title: Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-κB pathways in diabetic neuropathy.
abstract: The Nuclear factor-2 erythroid related factor-2 (Nrf2) is a redox regulated transcription factor involved in the regulation of antioxidant defence systems. It drives the production of endogenous antioxidant defences and detoxifying enzymes. Nuclear factor-kappa light chain enhancer of B cells (NF-κB) is a transcription factor, involved in proinflammatory cytokine production, in addition to its immunological function. Both Nrf2 and NF-κB regulation are co-ordinated in order to maintain redox homeostasis in healthy cells. However, during pathological conditions this regulation is perturbed offering an opportunity for therapeutic intervention. Diabetic neuropathy is a condition, in which change in expression pattern of Nrf2 and NF-κB has been reported. This review aims to focus on the role of the Nrf2 and NF-κB in diabetic neuropathy and summarizes the therapeutic outcomes of various pharmacological modulators targeted at the Nrf2-NF-κB axis in diabetic neuropathy.
authors.affiliation: Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Hyderabad, Bala Nagar, India.
authors.forename: Veera
authors.initials: V
authors.lastname: Ganesh Yerra
authors.forename: Geeta
authors.initials: G
authors.lastname: Negi
authors.forename: Shyam S
authors.initials: SS
authors.lastname: Sharma
authors.forename: Ashutosh
authors.initials: A
authors.lastname: Kumar
mesh_terms: D000818:Animals; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D051267:NF-E2-Related Factor 2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D051267:NF-E2-Related Factor 2; D016328:NF-kappa B
keywords: Diabetic neuropathy; NF-κB; Nrf2
references.citation: Curr Drug Targets. 2008 Jan;9(1):60-7
references.pmid: 18220713
references.citation: J Pineal Res. 2011 Mar;50(2):124-31
references.pmid: 21062351
references.citation: Curr Neurovasc Res. 2011 Nov;8(4):294-304
references.pmid: 22023613
references.citation: Biochim Biophys Acta. 2008 May;1783(5):713-27
references.pmid: 18241676
references.citation: Nanomedicine. 2013 Aug;9(6):776-85
references.pmid: 23347896
references.citation: Biochem Pharmacol. 2008 Dec 1;76(11):1485-9
references.pmid: 18694732
references.citation: Biochem Biophys Res Commun. 2010 Apr 2;394(2):360-5
references.pmid: 20211601
references.citation: Nature. 2001 Dec 13;414(6865):813-20
references.pmid: 11742414
references.citation: Antioxid Redox Signal. 2010 Dec 1;13(11):1649-63
references.pmid: 20367496
references.citation: Pharmacol Ther. 2008 Oct;120(1):1-34
references.pmid: 18616962
references.citation: Nat Neurosci. 2007 Nov;10(11):1361-8
references.pmid: 17965656
references.citation: Cell Signal. 2011 May;23(5):883-92
references.pmid: 21262351
references.citation: Redox Biol. 2013 Jan 18;1:45-9
references.pmid: 24024136
references.citation: Physiol Rev. 2013 Jan;93(1):137-88
references.pmid: 23303908
references.citation: Antioxid Redox Signal. 2005 Jul-Aug;7(7-8):889-99
references.pmid: 15998244
references.citation: J Immunol. 2004 Mar 15;172(6):3553-63
references.pmid: 15004156
references.citation: Nat Rev Drug Discov. 2004 Jan;3(1):17-26
references.pmid: 14708018
references.citation: Diabetes. 2005 Jun;54(6):1615-25
references.pmid: 15919781
references.citation: Diabetes. 2011 Feb;60(2):625-33
references.pmid: 21270272